Hormonal
Supplementation with 150 mg/day of quercetin for 6 weeks significantly reduces systolic blood pressure (SBP) in overweight or obese adults with high cardiovascular disease risk traits, with the effect being most pronounced in younger adults (25-50 years) and those with (pre-)hypertension.
If you are overweight or obese and have risk factors for heart disease (like high blood pressure or cholesterol), taking 150mg of quercetin daily for 6 weeks may help lower your systolic blood pressure by a few mmHg, especially if you are under 50. This is not a substitute for medication or lifestyle changes, but it may offer a small additional benefit. Note that it did not significantly change other lipid markers or inflammation in this group.
In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2·6 mmHg (P,0·01) in the entire study group, by 2·9 mmHg (P,0·01) in the subgroup of hypertensive subjects and by 3·7 mmHg (P,0·001) in the subgroup of younger adults aged 25 –50 years.
Why this rating
Double-blinded, placebo-controlled, cross-over design with a relatively large sample size (n=93) for a supplement trial, though limited to a specific high-risk phenotype.
Source
Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study
Sarah Egert et al. · British Journal Of Nutrition · 2009
DOI 10.1017/s0007114509359127
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →